- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04230343
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour
January 13, 2020 updated by: Burcu Isler, SB Istanbul Education and Research Hospital
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems.
Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination.
This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
244
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Istanbul, Turkey, 34098
- SB Istanbul Training and Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients hospitalized at medical departments of the hospital who are on the day of discharge
Exclusion Criteria:
- Egg ellergy
- Previous allergic reaction to influenza vaccine
- Pregnancy
- Cognitive disability
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Self-benefit arm
|
A pamphlet consisting of a short text and an abstract figure.
The top half of the pamphlet described the official criteria for qualifying to be in the risk group.
Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
|
Active Comparator: Social-benefit arm
|
A pamphlet consisting of a short text and an abstract figure.
The top half of the pamphlet described the official criteria for qualifying to be in the risk group.
Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others.
The figure included one smiley face surrounded by three other smiley faces.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine uptake following the introduction of the pamphlet
Time Frame: On the same day, upto 24 hours
|
Difference in the number of patients in each arm who agree to receive influenza vaccine following the introduction of the pamphlet.
The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases.
The second half introduces the self-benefit message.
And the final part asks if the participant wants to receive the influenza vaccine now.
|
On the same day, upto 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine uptake in high and low risk group patients following the introduction of the pamphlet
Time Frame: On the same day, upto 24 hours
|
Vaccine uptake in high and low risk group patients.
The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases.
The second half introduces the social-benefit message.
And the final part asks if the participant wants to receive the influenza vaccine now.
|
On the same day, upto 24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 13, 2016
Primary Completion (Actual)
March 25, 2017
Study Completion (Actual)
March 25, 2017
Study Registration Dates
First Submitted
January 12, 2020
First Submitted That Met QC Criteria
January 13, 2020
First Posted (Actual)
January 18, 2020
Study Record Updates
Last Update Posted (Actual)
January 18, 2020
Last Update Submitted That Met QC Criteria
January 13, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 855 - 21/10/2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza Vaccine
-
University of PittsburghMerck Sharp & Dohme LLC; PfizerCompletedAdolescent HPV Vaccine | Adolescent Influenza VaccineUnited States
-
Universität des SaarlandesFederal Institute of Sport ScienceCompletedInfluenza Virus Vaccine Adverse Reaction | Influenza Vaccine Allergy
-
The Jackson LaboratoryNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsRecruitingAging | Influenza Vaccine | Vaccine Response | Dendritic CellUnited States
-
Butantan InstituteUniversity of Sao Paulo; Insituto Adolfo Lutz; Centro de Referencia e Treinamento...CompletedImmunocompromised Patients | Safety of Pandemic Influenza A (H1N1)Vaccine | Immunogenicity of Pandemic Influenza A (H1N1)VaccineBrazil
-
University of Southern CaliforniaUniversity of California, Los Angeles; National Institute on Aging (NIA); Los...Completed
-
King's College LondonCompletedInfluenza Vaccine, InfluenzaUnited Kingdom
-
University of AlbertaUniversity of Lausanne HospitalsCompletedInfluenza Vaccine | Influenza VirusSwitzerland, Canada
-
Sinovac Biotech Co., LtdCenters for Disease Control and Prevention, ChinaCompletedPrevention | Pandemic Influenza | Pandemic Influenza VaccineChina
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
Novartis VaccinesCompletedProphylaxis of Avian Influenza VaccineUnited Kingdom
Clinical Trials on Self-benefit message
-
University of PennsylvaniaPennsylvania Department of HealthCompleted
-
University of PennsylvaniaDiscovery HealthCompletedDiabetes | Diet | Incentives | Messaging
-
University of California, Los AngelesCarnegie Mellon UniversityCompleted
-
University of RochesterNational Cancer Institute (NCI)Completed
-
University of MiamiTerminatedCervical CancerUnited States
-
Deniz AkyıldızRecruitingWomen's Breast Self Examination Beliefs | Women's Breast Self Examination PracticeTurkey
-
University of RochesterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedSmoking CessationUnited States
-
Miami UniversityNational Institute on Drug Abuse (NIDA); University of CincinnatiCompleted